Enalapril Maleate

ApprovedSmall molecule

GSK

Enalapril Maleate is one of 226 small molecule programs targeting Childhood Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

225

Competitors

Pipeline

Status by Indication[3][1]

Indication

Childhood CancerActive, not recruiting

StrokeActive, not recruiting

Kidney DiseaseActive, not recruiting

ProteinuriaActive, not recruiting

Breast CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

NephropathyActive, not recruiting

Childhood CancerPhase 3

Active, not recruiting

StrokeApproved

Active, not recruiting

Kidney DiseasePhase 2/Phase 3

Active, not recruiting

ProteinuriaPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

NephropathyPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Enalapril Maleate

GSK

Approved

1 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

MS Contin

Merck & Co.

Preclinical

2 7

Zolymbus

AbbVie

Preclinical

1 8

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 9

Tricor

JJagotec

Preclinical

1 10

Nubain

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cardiovascular Function1 trial

Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia

Completed·MManchester University NHS Foundation Trust·Phase 2·NCT03466333·118 enrolled

AML1 trial

A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study

Completed· GSK logo

GSK·Phase 1·NCT01822639·15 enrolled

Nephropathy1 trial

The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment

Completed·FFuling Central Hospital of Chongqing City·Phase 2/3·NCT02575092·4,000 enrolled

Kidney Disease1 trial

Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

Unknown status·OOmar Tarek Elfarargi·Phase 2/3·NCT05373004·212 enrolled

Stroke1 trial

China Stroke Primary Prevention Trial

Completed·SShenzhen Ausa Pharmed Co.,Ltd·Phase 4·NCT00794885·20,702 enrolled

5 more indications

Childhood Cancer1 trial

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

Completed·CChildren's Oncology Group·Phase 3·NCT00003070·13 enrolled

Chronic Kidney Disease1 trial

CSPPT- Chronic Kidney Diseases Study

Withdrawn·SShenzhen Ausa Pharmed Co.,Ltd·Phase 4·NCT01871740

Rheumatoid Arthritis1 trial

Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.

Completed·UUniversity of Guadalajara·Phase 2·NCT03667131·59 enrolled

Breast Cancer1 trial

Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00895414·19 enrolled

Proteinuria1 trial

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Completed·OOrganon and Co·Phase 3·NCT00568178·306 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Enalapril Maleate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enalapril Maleate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enalapril Maleate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Enalapril Maleate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cardiovascular Function1 trial

AML1 trial

Nephropathy1 trial

Kidney Disease1 trial

Stroke1 trial

Childhood Cancer1 trial

Chronic Kidney Disease1 trial

Rheumatoid Arthritis1 trial

Breast Cancer1 trial

Proteinuria1 trial

References

Drug Info

Quick Facts

Related News